A method for constructing a fingerprint spectrum of Allium macrostemon and determining the content of its indicative components.

By constructing a fingerprint spectrum of Allium macrostemon and determining the content of index components using liquid chromatography-mass spectrometry, the consistency problem in the quality evaluation of Allium macrostemon was solved, and stable and comprehensive quality control and evaluation of Allium macrostemon was achieved.

CN120177660BActive Publication Date: 2026-11-10MACAU UNIV OF SCI & TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510381568.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-28
Publication Date
2026-11-10
Estimated Expiration
2043-03-28

AI Technical Summary

Technical Problem

The existing technology lacks a consistent evaluation standard for the quality of Allium macrostemon from different origins. The existing fingerprint spectrum of Allium macrostemon has poor specificity and is difficult to reflect the evaluation of its active ingredients. The 2020 edition of the Chinese Pharmacopoeia also lacks a standard for the determination of the content of index components of Allium macrostemon.

Method used

This invention provides a method for constructing a fingerprint spectrum of Allium macrostemon (Xiebai) medicinal material. By using liquid chromatography-mass spectrometry (LC-MS) and optimizing the liquid phase elution method, the active components of steroidal saponins can be effectively separated and identified, a fingerprint spectrum of Allium macrostemon (Xiebai) medicinal material can be established, and the content of index components can be determined by LC-MS.

Benefits of technology

It enables stable and comprehensive quality evaluation of Allium macrostemon, ensuring the efficacy and safety of the herb, providing overall property control standards, and improving the controllability of Allium macrostemon quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120177660B_ABST
    Figure CN120177660B_ABST
Patent Text Reader

Abstract

This invention relates to a method for constructing a fingerprint spectrum of Allium macrostemon (Xanthium sibiricum) and determining the content of its indicative components. The method includes: preparing a test solution from Allium macrostemon; injecting the test solution into a liquid chromatography-mass spectrometry (LC-MS) instrument; obtaining the fingerprint spectrum of the Allium macrostemon using LC-MS; and determining the content of the indicative components. The method for constructing a fingerprint spectrum and determining the content of Allium macrostemon provided by this invention comprehensively improves the evaluation criteria for Allium macrostemon and ensures the effectiveness of its clinical use.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention is a divisional application of application No. 202310314133.5, filed on March 28, 2023, entitled "A method for constructing a fingerprint spectrum of Allium macrostemon and determining the content of index components of Allium macrostemon". Technical Field

[0002] This invention belongs to the field of traditional Chinese medicine quality analysis and testing technology, specifically relating to a method for constructing a fingerprint spectrum of Allium macrostemon and determining the content of its indicative components. Background Technology

[0003] First recorded in the *Shennong Bencao Jing* (Shennong's Classic of Materia Medica), *Allium macrostemon* Bge. or *Allium chinense* G.Don, belonging to the Liliaceae family, *Allium macrostemon* Bge. or *Allium chinense* G.Don, is known for its effects of promoting yang, dispersing stagnation, regulating qi, and relieving stagnation. It is used to treat chest pain, abdominal distension and pain, and tenesmus after diarrhea. Modern pharmacological studies suggest that *Allium macrostemon* has effects such as inhibiting platelet aggregation, lowering blood lipids, and resisting atherosclerosis, with steroidal saponins being its main active components. For example, 25S-Timosaponin B II and 25R-Timosaponin B II can inhibit ADP-induced platelet aggregation in vitro, while 25S-Timosaponin B II also has a good inhibitory effect on arachidonic acid (AA)-induced platelet aggregation.

[0004] Allium macrostemon is mainly produced in Shaanxi and Northeast China, and is distributed in most parts of the country. Effective technical means are needed to conduct consistent quality evaluation of Allium macrostemon to ensure the safety, efficacy, and quality control of this medicinal material.

[0005] However, no control standard has yet been established to consistently evaluate the quality of Allium macrostemon from different origins. Current research on the fingerprint spectrum of Allium macrostemon focuses only on its use in combination with other medicinal materials such as Trichosanthes kirilowii, Citrus aurantium, and Cinnamomum cassia. Moreover, the identified peaks are mostly nucleoside compounds, which have poor specificity and are difficult to reflect the evaluation of the active ingredients of Allium macrostemon. The 2020 edition of the Chinese Pharmacopoeia also lacks standards for determining the content of indicative components of Allium macrostemon.

[0006] Therefore, there is an urgent need to develop a method for constructing fingerprint spectra and determining the content of Allium macrostemon in order to apply it to the quality evaluation of Allium macrostemon. Summary of the Invention

[0007] The present invention aims to at least partially solve one of the technical problems existing in the prior art. To this end, the present invention provides a method for constructing a fingerprint spectrum of Allium macrostemon and determining the content of index components of Allium macrostemon.

[0008] According to one aspect of the present invention, a method for constructing a fingerprint spectrum of Allium macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II is provided, comprising: preparing a test solution from Allium macrostemonoside I; preparing a reference solution from Macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II; injecting the test solution and the reference solution into a liquid chromatography-mass spectrometry instrument, respectively, and obtaining the fingerprint spectrum of Allium macrostemonoside I according to the liquid chromatography-mass spectrometry method.

[0009] Preferably, the fingerprint spectrum of the Allium macrostemonoside contains 11 characteristic peaks, numbered peak 1 to peak 11; peak 3 is Macrostemonoside I, peak 6 is 25S-Timosaponin B II, and peak 7 is 25R-Timosaponin B II. The characteristic peaks in the LC-MS fingerprint spectrum and their identification are as follows:

[0010]

[0011] Preferably, peak 6 is designated as peak S, and the relative retention time ranges of peaks 1 to 5 and peaks 7 to 11 relative to peak S are 0.332 to 0.338, 0.362 to 0.367, 0.562 to 0.569, 0.588 to 0.593, 0.606 to 0.611, 1.036 to 1.039, 1.177 to 1.187, 1.216 to 1.229, 1.272 to 1.284, and 1.319 to 1.335, respectively.

[0012] Preferably, peak 6 is taken as the S peak, and the relative retention times (RSD) of peaks 1 to 5 and peaks 7 to 11 relative to the S peak are 0.46%, 0.42%, 0.32%, 0.25%, 0.22%, 0.08%, 0.24%, 0.32%, 0.27%, and 0.33%, respectively.

[0013] Preferably, the chromatographic conditions of the liquid chromatography-mass spectrometry (LC-MS) method include: stationary phase: a chromatographic column packed with octadecylsilane-bonded silica gel; mobile phase: mobile phase A is water containing 0.1% formic acid by volume, and mobile phase B is a solution of formic acid acetonitrile containing 0.1% formic acid by volume; gradient elution is used, and the flow rate is 0.3 mL / min.

[0014] Preferably, the chromatographic column is a CORTECS UPLC T3 Column (2.1×100mm, 1.6μm).

[0015] Preferably, the gradient elution is performed according to the following procedure: 0–0.5 min: mobile phase A from 85% to 85%, mobile phase B from 15% to 15%; 0.5–3.8 min: mobile phase A from 85% to 81%, mobile phase B from 15% to 19%; 3.8–4.5 min: mobile phase A from 81% to 77%, mobile phase B from 19% to 23%; 4.5–12.5 min: mobile phase A from 77% to 77%, mobile phase B from 23% to 23%; 12.5–14.0 min: mobile phase A from 77% to 73%, mobile phase B from 23% to 27%.

[0016] Preferably, the mass spectrometry conditions for the liquid chromatography-mass spectrometry (LC-MS) method include: detection in negative ion mode; ESI ion source; backflushing nitrogen temperature 325°C, backflushing nitrogen flow rate 11.0 L / min, nebulizer gas flow rate 45 psig, auxiliary nitrogen temperature 350°C, auxiliary nitrogen flow rate 11.0 L / min, capillary voltage 3500 V, in-source collision voltage 175 V, cone voltage 65.0 V; scanning mode: full scan; scanning range: m / z 60~1700.

[0017] Preferably, the method for preparing the test solution includes: extracting, weighing, and filtering the Allium macrostemon using a first solvent to obtain the test solution.

[0018] Preferably, the preparation method of the test solution includes: taking 50 mg of the Allium macrostemon; adding 1 ml of the first solvent, soaking for 60 minutes and then weighing for the first time; ultrasonically extracting for 60 minutes at 40 kHz and 30 °C; cooling and then weighing for the second time, and continuing to add the first solvent to make up for the weight loss; filtering to obtain the test solution, wherein the first solvent is 50%-95% ethanol.

[0019] According to another aspect of the present invention, a method for determining the content of indicative components of Allium macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II is provided, comprising: preparing a sample solution of Allium macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II as reference solutions; injecting the sample solution and the reference solutions into a liquid chromatography-mass spectrometry (LC-MS) instrument, respectively, and obtaining a chromatogram of the Allium macrostemonoside I and a reference chromatogram of the reference solutions according to the determined LC-MS method; calculating the content of indicative components Macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II in the Allium macrostemonoside I, based on the concentration of the reference solution, the peak area of ​​the reference solution in the reference chromatogram, and the peak areas of the corresponding components of the Allium macrostemonoside I and the reference solution in the chromatogram of the sample solution.

[0020] Preferably, the concentration of the reference solution and the peak area of ​​the reference solution in the reference chromatogram satisfy the following relationship: the first regression equation of Macrostemonoside I is y = 191254.78x - 6525.86(r 2 =0.9997 (unweighted), the linear range is 0.25-25 μg / mL, the limit of detection is 0.05 μg / mL (S / N≥3), and the limit of quantitation is 0.25 μg / mL (S / N≥9); the second regression equation of the 25S-Timosaponin B II is y = 356910.66x - 18259.39 (r 2 =0.9996, weight 1 / x), linear range 0.25-25 μg / mL, detection limit 0.05 μg / mL (S / N≥3), quantitation limit 0.25 μg / mL (S / N≥9); the third regression equation for the 25R-Timosaponin B II is y = 480774.43x - 17621.70 (r 2 =0.9995, weight is 1 / x), linear range is 0.25-25 μg / mL, detection limit is 0.05 μg / mL (S / N≥3), quantitation limit is 0.25 μg / mL (S / N≥9); wherein, in the first regression equation, the second regression equation, and the third regression equation, the x-axis is the concentration of the reference solution, and the y-axis is the peak area in the reference chromatogram.

[0021] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides a method for constructing a fingerprint spectrum of Allium macrostemon and determining the content of index components. This method achieves effective separation of steroidal saponin active components by optimizing the liquid chromatography elution method; it utilizes the precise molecular weight, molecular composition and fragment information of compounds obtained by liquid chromatography-mass spectrometry to identify and characterize the chromatographic peaks in the fingerprint spectrum; and it establishes a quantitative analysis method for the main steroidal saponin components in Allium macrostemon. The present invention stably and comprehensively improves the evaluation criteria of Allium macrostemon, ensures the effectiveness of the medicinal material in clinical use, and provides a reference for the overall control of the quality of Allium macrostemon. Attached Figure Description

[0022] The accompanying drawings, which are included to provide a further understanding of the invention and form part of this application, illustrate exemplary embodiments of the invention and, together with their description, serve to explain the invention and do not constitute an undue limitation thereof. In the drawings:

[0023] Figure 1 The chromatogram of the Allium macrostemon test solution under elution method-1 is shown;

[0024] Figure 2 The chromatogram of the Allium macrostemon test solution under elution method-2 is shown;

[0025] Figure 3 A comparison chart of the reference solution chromatogram and the fingerprint chromatogram of Allium macrostemon is shown; and

[0026] Figure 4 The fingerprint spectra of 16 batches of Allium macrostemon provided by the present invention are shown in Table 1, where the sample numbers are shown in Table 1 and R is the control fingerprint spectra. Detailed Implementation

[0027] The following examples are provided to help those skilled in the art better understand the present invention. It should be noted that the following examples do not constitute a limitation on the scope of protection claimed by the present invention, but are merely illustrative examples. Unless otherwise specified, the raw materials, reagents, or devices mentioned in the following examples can be obtained commercially or through known existing methods. The origin information of the Allium macrostemon used in this invention is shown in Table 1.

[0028] Table 1: Origin Information of 16 Batches of Allium macrostemon Medicinal Materials

[0029]

[0030]

[0031] Example 1

[0032] Method for constructing fingerprint spectrum of Allium macrostemon.

[0033] This embodiment provides a method for constructing a fingerprint spectrum of Allium macrostemon I, comprising: preparing a test solution from Allium macrostemon I; preparing reference solutions from Macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II; injecting the test solution and reference solutions into a liquid chromatography-mass spectrometry (LC-MS) instrument, and obtaining the fingerprint spectrum of Allium macrostemon I using LC-MS. Specific construction methods are provided below.

[0034] 1. Preparation of the test solution

[0035] Accurately weigh 50 mg of Allium macrostemon powder (passed through a No. 3 sieve) (error less than 0.05 mg), add 1 mL of 50%-95% ethanol, soak for 60 min, weigh, extract ultrasonically for 60 min (40 kHz, 30 °C), cool, weigh again, replenish the weight loss with 50%-95% ethanol, shake well, transfer the supernatant to obtain the LC-MS fingerprint test solution, wherein the ethanol is preferably 75%.

[0036] 2. Preparation of reference solution

[0037] Accurately weigh 1 mg each of Macrostemonoside I, 25S-Timosaponin B II and 25R-Timosaponin B II, add them to a 50% volume concentration methanol solution to prepare a 1 mg / mL reference stock solution, and then mix an appropriate amount of the reference stock solution to prepare a mixed reference solution with a concentration of 25 μg / mL.

[0038] 3. Optimization of conditions for liquid chromatography-mass spectrometry

[0039] Take the preset amounts of reference solution and test solution, inject them into the LC-MS liquid chromatography-mass spectrometry instrument, use octadecylsilane-bonded silica gel as the stationary phase, use a mobile phase A containing 0.1% formic acid aqueous solution as mobile phase A and a mobile phase B containing 0.1% formic acid acetonitrile solution as mobile phase B for gradient elution, the flow rate is 0.3 mL / min, and construct the LC-MS fingerprint spectrum of Allium macrostemon.

[0040] The high-resolution mass spectrometry detection conditions were as follows: detection in negative ion mode; ESI ion source; backflushing nitrogen temperature 325℃, backflushing nitrogen flow rate 11.0 L / min, nebulizing gas flow rate 45 psig, auxiliary nitrogen temperature 350℃, auxiliary nitrogen flow rate 11.0 L / min, capillary voltage 3500 V, source collision voltage 175 V, cone voltage 65.0 V; scanning mode: full scan; scanning range: m / z 60~1700.

[0041] 3.1 Optimization of liquid chromatography elution method

[0042] Based on previous research on the components of Allium macrostemon, under the above liquid chromatography-mass spectrometry conditions, steroidal saponins mainly eluted within a linear range from 15% to 40% in mobile phase B (mobile phase A was a 0.1% (v / v) formic acid aqueous solution, and mobile phase B was a 0.1% (v / v) formic acid acetonitrile solution). Based on the above experimental results, an optimized LC-MS fingerprint gradient elution method-1 was developed, and the elution gradient is shown in Table 2.

[0043] Table 2: Gradient elution table of LC-MS fingerprint patterns

[0044]

[0045] Based on the gradient elution method-1 of LC-MS fingerprinting, the results showed that 11 compound peaks warranted attention, among which 3 pairs of isomers were expected to achieve baseline separation: peaks 6 and 7, 8 and 9, and 10 and 11. The chromatogram of the Allium macrostemon sample solution under elution method-1 is shown below. Figure 1 Therefore, based on LC-MS fingerprint gradient elution method-1, LC-MS fingerprint gradient elution method-2 was optimized to obtain (…). Figure 2 The elution gradient is shown in Table 3.

[0046] Table 3: Gradient elution table of LC-MS fingerprint patterns

[0047]

[0048] Based on the LC-MS fingerprint gradient elution method-2 experiment, the results showed that the retention times of peaks 1 to 5 were significantly forward, the peak shapes were intact, and the separation effect was good, which is beneficial to shortening the detection time. Under the condition of maintaining a 23% isogradient elution with mobile phase B from 4.5 min to 12.5 min, the peaks of the three pairs of isomers were all baseline separated, which is beneficial to the subsequent establishment of a quantitative method for steroidal saponins. The chromatogram of the Allium macrostemon test solution under elution method-2 is shown in [Figure 2]. Figure 2 .

[0049] 3.2 Determination of Liquid Chromatography Conditions

[0050] A CORTECS UPLC T3 column (2.1 × 100 mm, 1.6 μm) was used as the elution column. The mobile phase A was an aqueous solution containing 0.1% formic acid (v / v) and the mobile phase B was an acetonitrile solution containing 0.1% formic acid (v / v). The flow rate was 0.3 mL / min and the column temperature was 30 °C. Gradient elution was performed according to the following procedure.

[0051] From 0 to 0.5 min, mobile phase A decreased from 85% to 85%, and mobile phase B decreased from 15% to 15%.

[0052] Over 0.5–3.8 min, mobile phase A decreased from 85% to 81%, and mobile phase B decreased from 15% to 19%.

[0053] Over 3.8–4.5 min, mobile phase A decreased from 81% to 77%, and mobile phase B decreased from 19% to 23%.

[0054] From 4.5 to 12.5 min, mobile phase A decreased from 77% to 77%, and mobile phase B decreased from 23% to 23%.

[0055] Over 12.5–14 minutes, mobile phase A decreased from 77% to 73%, and mobile phase B decreased from 23% to 27%.

[0056] 4. Identification of chemical composition from LC-MS fingerprints

[0057] The reference solution and the test solution were detected by LC-MS. By comparing the retention time, precise molecular weight and fragmentation pattern of the chromatographic peaks, three compounds corresponding to the chromatographic peaks were identified as Macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II. Using LC-MS, and by comparing the structures and retention times with those reported in the literature, combined with the fragmentation patterns of the secondary chromatograms, a total of 8 compounds corresponding to the chromatographic peaks were identified. These compounds were Macrostemonoside G or its isomers, Elephanoside E or its isomers, 25R-Macrostemonoside I or its isomers, (25R)-12α-OH-timosaponin B II or its isomers, 5(6)-ene-25S-Macrostemonoside B or its isomers, 5(6)-ene-25R-Macrostemonoside B or its isomers, 25S-Macrostemonoside B or its isomers, and 25R-Macrostemonoside B or its isomers.

[0058] The fingerprint spectrum of Allium macrostemonoside contains 11 characteristic peaks, numbered 1 to 11; peak 3 is Macrostemonoside I, peak 6 is 25S-Timosaponin B II, and peak 7 is 25R-Timosaponin B II, as detailed in Table 4.

[0059] Table 4: Characteristic peaks of LC-MS and their identification

[0060]

[0061] With peak 6 as the S peak, the relative retention time ranges of peaks 1 to 5 and peaks 7 to 11 relative to the S peak are 0.332–0.338, 0.362–0.367, 0.562–0.569, 0.588–0.593, 0.606–0.611, 1.036–1.039, 1.177–1.187, 1.216–1.229, 1.272–1.284, and 1.319–1.335.

[0062] With peak 6 as the S peak, the relative retention times (RSDs) of peaks 1-5 and peaks 7-11 relative to the S peak are 0.46%, 0.42%, 0.32%, 0.25%, 0.22%, 0.08%, 0.24%, 0.32%, 0.27%, and 0.33%, respectively.

[0063] Figure 3 A comparison chart of the reference solution chromatogram and the fingerprint chromatogram of Allium macrostemon is shown.

[0064] 5. Fingerprint Similarity Evaluation

[0065] The LC-MS fingerprint chromatograms of 16 batches of Allium macrostemon test solutions in txt format were imported into the "Traditional Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" (2012 version) software, and the similarity of each fingerprint chromatogram was calculated. The results are shown in Table 5.

[0066] The results showed that, using the 25S-Timosaponin BⅡ chromatographic peak (peak 6) as the reference peak S, a reference chromatogram was generated using the average method to establish a reference fingerprint chromatogram for Allium macrostemon. The superimposed fingerprint chromatograms of Allium macrostemon were obtained, and the similarity was calculated. The similarity of the fingerprint chromatograms of 16 Allium macrostemon samples was between 0.985 and 0.999, indicating that the fingerprint chromatogram can effectively evaluate the quality of Allium macrostemon.

[0067] Figure 4 The fingerprint chromatograms of 16 batches of Allium macrostemon provided by this invention are shown in Table 1, where the sample numbers are listed in Table 1 and R is the control fingerprint chromatogram.

[0068] Table 5: Similarity of LC-MS fingerprint spectra of 16 batches of Allium macrostemon medicinal materials

[0069]

[0070] Example 2

[0071] This embodiment provides a method for determining the content of indicative components in Allium macrostemonoside I, 25S-Timosaponin BII, and 25R-Timosaponin BII, comprising: preparing a sample solution from the Allium macrostemonoside I to be tested; preparing reference stock solutions of Macrostemonoside I, 25S-Timosaponin BII, and 25R-Timosaponin BII, and mixing the reference stock solutions to obtain a reference solution; injecting the sample solution and the reference solution into a liquid chromatography-mass spectrometry (LC-MS) instrument, and obtaining the chromatogram of the Allium macrostemonoside I and the reference solution according to the LC-MS method determined in Example 2; calculating the content of indicative components Macrostemonoside I, 25S-Timosaponin BII, and 25R-Timosaponin BII in the Allium macrostemonoside I to be tested based on the concentration of the reference solution, the peak area of ​​the reference solution in the reference chromatogram, and the peak areas of the corresponding components of the Allium macrostemonoside I and the reference solution in the chromatogram of the sample solution. Specific determination methods are provided below.

[0072] 1. Selection of experimental conditions for the determination method

[0073] The UHPLC-Q-TOF-MS conditions were as follows: a CORTECS UPLC T3 column (2.1 × 100 mm, 1.6 μm), a flow rate of 0.3 mL / min, and a column temperature of 30 °C. The eluent consisted of an aqueous solution containing 0.1% formic acid (mobile phase A) and an acetonitrile solution containing 0.1% formic acid (mobile phase B). The injection volume was 1 μL, and gradient elution was performed according to the following procedure.

[0074] From 0 to 0.5 min, mobile phase A decreased from 85% to 85%, and mobile phase B decreased from 15% to 15%.

[0075] Over 0.5–3.8 min, mobile phase A decreased from 85% to 81%, and mobile phase B decreased from 15% to 19%.

[0076] Over 3.8–4.5 min, mobile phase A decreased from 81% to 77%, and mobile phase B decreased from 19% to 23%.

[0077] From 4.5 to 12.5 min, mobile phase A decreased from 77% to 77%, and mobile phase B decreased from 23% to 23%.

[0078] Over 12.5–14 minutes, mobile phase A decreased from 77% to 73%, and mobile phase B decreased from 23% to 27%.

[0079] Mass spectrometry detection was performed in ESI negative ion mode, with ESI as the ion source; backflushing nitrogen temperature was 325℃, backflushing nitrogen flow rate was 11.0 L / min, nebulizer gas flow rate was 45 psig, auxiliary nitrogen temperature was 350℃, auxiliary nitrogen flow rate was 11.0 L / min, capillary voltage was 3500 V, in-source collision voltage was 175 V, and cone voltage was 65.0 V; scanning mode: full scan; scanning range: m / z 60~1700.

[0080] 2. Methodological Validation

[0081] Method validation items include limit of detection, limit of quantitation, linear range, precision, accuracy, recovery, matrix effect, and stability.

[0082] 2.1 Limit of detection, limit of quantitation, and linear range

[0083] Preparation of standard solutions: Accurately weigh 1 mg each of Macrostemonoside I, 25S-Timosaponin B II and 25R-Timosaponin B II, add them to 50% methanol solution to prepare a 1 mg / mL reference stock solution, and then mix an appropriate amount of the reference stock solution to prepare a mixed reference solution with a concentration of 25 μg / mL.

[0084] The mixed reference solution was diluted to concentrations of 0.05–25 μg / mL to prepare a series of working solutions. The stock solution was diluted to three concentrations: low (1 μg / mL), medium (5 μg / mL), and high (10 μg / mL) as quality control samples for the mixed reference. A linear regression was performed on the standard curve with concentration on the x-axis and peak area on the y-axis to obtain the standard curve: The standard curve for Macrostemonoside I is y = 191254.78x - 6525.86 (r... 2 =0.9997 (unweighted), linear range is 0.25-25 μg / mL, detection limit is 0.05 μg / mL (S / N≥3), quantitation limit is 0.25 μg / mL (S / N≥9); the standard curve of 25S-Timosaponin B II is y = 356910.66x - 18259.39 (r 2 =0.9996, weight 1 / x), linear range 0.25-25 μg / mL, detection limit 0.05 μg / mL (S / N≥3), quantitation limit 0.25 μg / mL (S / N≥9); the standard curve of 25R-Timosaponin B II is y = 480774.43x - 17621.70 (r 2=0.9995, weight 1 / x), linear range 0.25-25 μg / mL, detection limit 0.05 μg / mL (S / N≥3), quantitation limit 0.25 μg / mL (S / N≥9).

[0085] 2.2 Precision, accuracy, recovery rate, matrix effect, and stability

[0086] Low, medium, and high concentration quality control samples were each tested three times on the same day. The relative standard deviation (RSD) of the peak areas of the three analytes was calculated to obtain the intra-day precision. The inter-day precision was obtained by injecting and testing the low, medium, and high concentration quality control samples three times a day for three consecutive days. Accuracy was evaluated by the percentage ratio of the detected concentration to the actual concentration of the quality control sample. The experimental results showed that the intra-day and inter-day precision of the low, medium, and high concentration quality control samples were within ±15%, and the intra-day and inter-day accuracy were between 85% and 115%, which met the requirements.

[0087] Recovery and matrix effect experiments were conducted by adding low, medium, and high concentration quality control samples to the samples. The recovery rate and matrix effect were obtained according to the following formula. The results showed that the recovery rate and matrix effect of the low, medium, and high concentration quality control samples were all between 85% and 115%, which met the requirements.

[0088]

[0089] Stability was calculated by measuring the peak areas of the same low, medium, and high concentration quality control samples after they were placed at 4°C for 24 hours. The results showed that the RSD of the stability measurements for the low, medium, and high concentration quality control samples was within ±15%, meeting the requirements.

[0090] The results above (Tables 6 and 7) show that the established quantitative method can stably and accurately quantify steroidal saponins in Allium macrostemon samples.

[0091] Table 6: Precision and Accuracy Test Results of Steroidal Saponin Standards

[0092]

[0093]

[0094] Table 7: Results of experiments on the stability, recovery rate and matrix effect of steroidal saponin standards

[0095]

[0096] 2.3 Determination of the content of indicative components in 16 batches of Allium macrostemon medicinal materials

[0097] Accurately weigh 50 mg of each of 16 batches of Allium macrostemonoside powder, prepare test solutions according to the method in Example 2, and perform analysis under the UHPLC-Q-TOF-MS conditions in this example. Record the peak area and calculate the content of Macrostemonoside I in Allium macrostemonoside samples from different origins as 0.012% ± 0.003%, 25S-Timosaponin B II as 0.011% ± 0.003%, and 25R-Timosaponin B II as 0.034% ± 0.006%. The specific determination results are shown in Table 8.

[0098] Table 8: Quantitative results of steroidal saponins in 16 batches of Allium macrostemon

[0099]

[0100]

[0101] *The content calculation formula is: Content in Allium macrostemon sample = m / M × 100% (where m is the content of the analyte compound in the sample detected by linear detection, and M is the initial mass of Allium macrostemon powder).

[0102] In summary, this invention provides a method for constructing a fingerprint spectrum of Allium macrostemon and determining the content of its indicative components. This method overcomes the previous problem of poor specificity in Allium macrostemon fingerprint spectra, optimizes the liquid chromatography elution method, effectively separates the peaks of steroidal saponin active ingredients, and establishes an LC-MS fingerprint spectrum. The similarity of 16 batches of Allium macrostemon samples was between 0.985 and 0.999, indicating that this fingerprint spectrum can effectively evaluate the quality of Allium macrostemon. Based on this liquid chromatography elution method, a UHPLC-Q-TOF-MS quantitative detection method was established to determine the content of major steroidal saponins (Macrostemonoside I, 25S-Timosaponin B II, and 25R-Timosaponin B II) in Allium macrostemonoside. The results showed that the content of Macrostemonoside I in Allium macrostemonoside samples from different origins was 0.012% ± 0.003%, the content of 25S-Timosaponin B II was 0.011% ± 0.003%, and the content of 25R-Timosaponin B II was 0.034% ± 0.006%. This method improves the evaluation criteria for Allium macrostemonoside and provides a reference for the overall and comprehensive quality control of Allium macrostemonoside.

[0103] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A method for constructing a fingerprint spectrum of Allium macrostemon, characterized in that, include: A test solution was prepared from Allium macrostemon. The preparation method of the test solution includes: extracting the Allium macrostemon with a first solvent, adding weight, and filtering to obtain the test solution; the first solvent is 50%-95% ethanol. Macrostemonoside I, 25S-Timosaponin B II and 25R-Timosaponin B II were prepared as reference solutions; The test solution and the reference solution were injected into a liquid chromatography-mass spectrometry instrument, and the fingerprint spectrum of the Allium macrostemon was obtained according to the liquid chromatography-mass spectrometry method. The chromatographic conditions for the liquid chromatography-mass spectrometry method include: Stationary phase: CORTECS UPLC T3 Column, 2.1 × 100 mm, 1.6 μm, for elution; Mobile phase: Mobile phase A is water containing 0.1% formic acid by volume, and mobile phase B is acetonitrile solution containing 0.1% formic acid by volume; Gradient elution was used at a flow rate of 0.3 mL / min and a column temperature of 30℃. The gradient elution is performed according to the following procedure: 0~0.5min: Mobile phase A changes from 85% to 85%, mobile phase B changes from 15% to 15%; 0.5~3.8 min: Mobile phase A changes from 85% to 81%, mobile phase B changes from 15% to 19%; 3.8~4.5 min: Mobile phase A changes from 81% to 77%, mobile phase B changes from 19% to 23%; 4.5~12.5 min: Mobile phase A changes from 77% to 77%, mobile phase B changes from 23% to 23%; 12.5~14.0 min: Mobile phase A changes from 77% to 73%, mobile phase B changes from 23% to 27%; The mass spectrometry conditions for the liquid chromatography-mass spectrometry (LC-MS) method include: Detection was performed in negative ion mode; The ion source is ESI; Backflush nitrogen temperature 325℃, backflush nitrogen flow rate 11.0L / min, atomizing gas flow rate 45psig, auxiliary nitrogen temperature 350℃, auxiliary nitrogen flow rate 11.0L / min, capillary voltage 3500V, source collision voltage 175V, cone voltage 65.0V. Scanning mode: Full scan; Scan range: m / z 60~1700; The fingerprint spectrum of the Allium macrostemon contains 11 characteristic peaks, which are numbered as peak 1 to peak 11. The characteristic peaks and their identification are as follows: 。 2. The construction method according to claim 1, characterized in that, Taking peak 6 as the S peak, the relative retention time ranges of peaks 1-5 and peaks 7-11 relative to the S peak are as follows: 0.332~0.338、0.362~0.367、0.562~0.569、0.588~0.593、0.606~0.611、1.036~1.039、1.177~1.187、1.216~1.229、1.272~1.284、1.319~1.335。 3. The construction method according to claim 2, characterized in that, Taking peak 6 as the S peak, the relative retention times (RSD) of peaks 1-5 and 7-11 relative to the S peak are as follows: 0.46%、0.42%、0.32%、0.25%、0.22%、0.08%、0.24%、0.32%、0.27%、0.33%。

Citation Information

Patent Citations

  • Specific chromatogram of allium macrostemon water extract and preparation thereof and construction method of specific chromatogram

    CN113759057A

  • Method for constructing HPLC characteristic chromatogram of fructus aurantii immaturus, allium macrostemon and cassia twig decoction

    CN114062563A